Literature DB >> 25370917

MCP-1 and CCR2 gene polymorphisms in Parkinson's disease in a Han Chinese cohort.

Liang Gao1, Hongmei Tang, Kun Nie, Limin Wang, Jiehao Zhao, Rong Gan, Jing Huang, Shujun Feng, Ruiming Zhu, Zhenpeng Duan, Youwen Zhang, Xin Zhao, Yuhu Zhang, Lijuan Wang.   

Abstract

Monocyte chemoattractant protein-1 (MCP-1) and its receptor CC chemokine receptor-2 (CCR2) play important roles in neuroinflammation and they have been shown to be involved in Parkinson's disease (PD) pathogenesis. In addition, several studies have suggested a role for the MCP-1 and CCR2 genotypes in cognitive impairment and depression, which are common non-motor symptoms in PD patients. In this study, a cohort of 521 PD patients and 556 cases of healthy controls were recruited to investigate the association between the MCP-1 2518A/G (rs1064211) and CCR2 V64I (rs1799864) gene polymorphisms and PD risk in the Chinese population. We also analyze the influence of these genotypes on the cognitive function and depression in PD patients by comparing Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Wechsler Adult Intelligence Scale-Chinese Revision (WAIS-RC), Wechsler Memory Scale-Chinese Revision (WMS-RC) and Hamilton Depression Rating Scale (HAMD) ratings in 217 PD patients. Our results showed no significant differences in the genotype frequency between the PD group and the control group (P > 0.05). In addition, we also failed to find an influence of the MCP-1 and CCR2 genotypes on MMSE scores, MoCA scores, WAIS-RC scores, WMS-RC scores and HAMD scores in PD patients (P > 0.05). The MCP-1 and CCR2 gene polymorphisms may not be genetic risk factors for PD in the Han Chinese population, and they do not appear to influence cognitive function and depression in PD patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25370917     DOI: 10.1007/s10072-014-1990-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  30 in total

1.  Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

Authors:  R Pattarini; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2007-01-29       Impact factor: 3.590

2.  Peripheral cytokines profile in Parkinson's disease.

Authors:  M Reale; C Iarlori; A Thomas; D Gambi; B Perfetti; M Di Nicola; M Onofrj
Journal:  Brain Behav Immun       Date:  2008-07-17       Impact factor: 7.217

Review 3.  Inflammation in neurodegenerative diseases--an update.

Authors:  Sandra Amor; Laura A N Peferoen; Daphne Y S Vogel; Marjolein Breur; Paul van der Valk; David Baker; Johannes M van Noort
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

4.  Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease.

Authors:  Cecilia Huerta; Victoria Alvarez; Ignacio F Mata; Eliecer Coto; René Ribacoba; Carmen Martínez; Marta Blázquez; Luis M Guisasola; Carlos Salvador; Carlos H Lahoz; Joaquín Peña
Journal:  Neurosci Lett       Date:  2004-11-11       Impact factor: 3.046

5.  Polymorphisms in immune/inflammatory cytokine genes are related to Parkinson's disease with cognitive impairment in the Han Chinese population.

Authors:  Kun Nie; Yuhu Zhang; Rong Gan; Limin Wang; Jiehao Zhao; Zhiheng Huang; Hongmei Tang; Lijuan Wang
Journal:  Neurosci Lett       Date:  2013-02-26       Impact factor: 3.046

6.  Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment.

Authors:  Daniel Lindqvist; Sara Hall; Yulia Surova; Henrietta M Nielsen; Shorena Janelidze; Lena Brundin; Oskar Hansson
Journal:  Brain Behav Immun       Date:  2013-07-31       Impact factor: 7.217

7.  Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release.

Authors:  A Guyon; D Skrzydelski; I De Giry; C Rovère; G Conductier; J M Trocello; V Daugé; P Kitabgi; W Rostène; J L Nahon; S Mélik Parsadaniantz
Journal:  Neuroscience       Date:  2009-05-27       Impact factor: 3.590

8.  A detailed examination of cytokine abnormalities in Major Depressive Disorder.

Authors:  N M Simon; K McNamara; C W Chow; R S Maser; G I Papakostas; M H Pollack; A A Nierenberg; M Fava; K K Wong
Journal:  Eur Neuropsychopharmacol       Date:  2007-08-03       Impact factor: 4.600

Review 9.  The role of innate and adaptive immunity in Parkinson's disease.

Authors:  George T Kannarkat; Jeremy M Boss; Malú G Tansey
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

10.  Cytokine production by leukocytes of military personnel with depressive symptoms after deployment to a combat-zone: a prospective, longitudinal study.

Authors:  Mirjam van Zuiden; Cobi J Heijnen; Rens van de Schoot; Karima Amarouchi; Mirjam Maas; Eric Vermetten; Elbert Geuze; Annemieke Kavelaars
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

View more
  4 in total

1.  Association of polymorphisms in the MCP-1 and CCR2 genes with the risk of Parkinson's disease.

Authors:  Yan Wang; Minhua Zhou; Yong Wang; Deqi Jiang; Xun Deng
Journal:  J Neural Transm (Vienna)       Date:  2019-08-30       Impact factor: 3.575

2.  Genetic variants of MCP-1 and CCR2 genes and IgA nephropathy risk.

Authors:  Jie Gao; Xinghan Liu; Linting Wei; Dan Niu; Jiali Wei; Li Wang; Heng Ge; Meng Wang; Qiaoling Yu; Tianbo Jin; Tian Tian; Zhijun Dai; Rongguo Fu
Journal:  Oncotarget       Date:  2016-11-22

3.  Polysaccharides from Ganoderma lucidum attenuate microglia-mediated neuroinflammation and modulate microglial phagocytosis and behavioural response.

Authors:  Qing Cai; Yuanyuan Li; Gang Pei
Journal:  J Neuroinflammation       Date:  2017-03-24       Impact factor: 8.322

4.  A Case-Control Association Study of RANTES (-28C>G) Polymorphism as a Risk Factor for Parkinson's Disease in Isparta, Turkey.

Authors:  Nilufer Sahin-Calapoglu; Serpil Demirci; Mustafa Calapoglu; Baris Yasar
Journal:  Parkinsons Dis       Date:  2016-12-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.